Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results & Recent Corporate Developments on Thursday, August 9
July 26 2018 - 8:00AM
Business Wire
The Company Will Host a Conference Call at
8:30am ET
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, will report second quarter 2018
financial results before the NASDAQ Global Market open on Thursday,
August 9, 2018. Jill C. Milne, Ph.D., Chief Executive Officer, will
host a conference call and webcast at 8:30am ET to provide an
update on corporate developments and to discuss second quarter
financial results.
Conference Call Dial-In
Information:
Participant Toll-Free Dial-In Number: (877)
388-2733 Participant International Dial-In Number: (541) 797-2984
Pass Code: 5876459
Please specify to the operator that you would like to join the
“Catabasis Second Quarter 2018 Results Call.”
Interested parties may access a live audio webcast of the
conference call via the investor section of the Catabasis website,
www.catabasis.com. Please connect to the Catabasis website several
minutes prior to the start of the broadcast to ensure adequate time
for any software download that may be necessary. The webcast will
be archived for 90 days.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy.
Edasalonexent was designed using our SMART (Safely Metabolized And
Rationally Targeted) Linker drug discovery platform that enables us
to engineer molecules that simultaneously modulate multiple targets
in a disease. For more information on edasalonexent or our drug
discovery platform, please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180726005024/en/
Investor and Media ContactCatabasis
Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024